Trial Search Results

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Meredith Mills
6507245223
Not Recruiting